- Home
- PENN vs ELVN Comparison
PENN vs ELVN Comparison
Compare PENN & ELVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PENN | ELVN |
|---|---|---|
| Founded | 1972 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PENN | ELVN |
|---|---|---|
| Price | $14.72 | $29.84 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 15 | 4 |
| Target Price | $20.29 | ★ $41.00 |
| AVG Volume (30 Days) | ★ 4.5M | 573.1K |
| Earning Date | 05-29-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.17 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $6,362,900,000.00 | N/A |
| Revenue This Year | $6.02 | N/A |
| Revenue Next Year | $4.31 | $40.06 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.65 | $13.30 |
| 52 Week High | $20.61 | $30.63 |
Technical Indicators
Market Signals| Indicator | PENN | ELVN |
|---|---|---|
| Relative Strength Index (RSI) | 56.53 | 63.60 |
| Support Level | $14.03 | $18.41 |
| Resistance Level | $15.21 | N/A |
| Average True Range (ATR) | 0.89 | 1.48 |
| MACD | 0.22 | 0.00 |
| Stochastic Oscillator | 76.39 | 89.31 |
Price Performance
Historical ComparisonAbout PENN PENN Entertainment Inc.
Penn Entertainment's origins date back to its 1972 racetrack opening in Pennsylvania. Today, Penn operates 43 properties across 20 states and 12 brands, including Hollywood Casino and Ameristar. Land-based casinos represented 85% of total sales in 2024; 15% was from the interactive segment, which includes sports, iGaming, and media revenue. The retail portfolio generates mid-30s EBITDAR margins and helps position the company to obtain licenses for the digital wagering markets. Additionally, Penn's media asset, theScore, provides access to sports betting/iGaming technology and clientele, helping it form a leading digital position.
About ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.